Editorial: More questions than answers: A call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial

Retina

Volumn 30, Issue 1, 2010, Pages 1-5

  Pulido, Jose S ^a   Pulido, Jose E ^b   Michet, Clement J ^c   Vile, Richard G ^d  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Mayo Clinic and Foundation ^*  (United States)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; BEVACIZUMAB; CARDIOLIPIN ANTIBODY; CD20 ANTIBODY; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; GOLIMUMAB; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN F(AB) FRAGMENT; INFLIXIMAB; MACROGOL; MONOCLONAL ANTIBODY; RANIBIZUMAB; RITUXIMAB; TRASTUZUMAB; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; ANTIIDIOTYPIC ANTIBODY; ANTIINFLAMMATORY AGENT;

ALBUMINURIA; ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; ANTIMICROBIAL ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; CACHEXIA; CELL ADHESION; CELL SURFACE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE RELEASE; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PENETRATION; DRUG STABILITY; EDITORIAL; ENDOTHELIUM; EYE CANCER; EYE CARE; EYE DISEASE; EYE INFLAMMATION; HEART FAILURE; HUMAN; IMMUNOTHERAPY; INFECTION; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY CELL; KIDNEY INJURY; LUPUS LIKE SYNDROME; LYMPHOCYTE; MALIGNANT CONDITION; NEOPLASM; NEUTROPHIL; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; OXIDATION; PEER REVIEW; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; RETINA; RETINA DISEASE; RETINA MACULA CYSTOID EDEMA; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SMOOTH MUSCLE FIBER; SUBRETINAL NEOVASCULARIZATION; TUBERCULIN TEST; TUBERCULOSIS; UVEITIS; VASODILATATION; VISION TEST; VITREOUS HEMORRHAGE; VITREOUS OPACITY; BLOOD; DRUG ANTAGONISM; INJECTION; VITREOUS BODY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG STABILITY; HUMANS; INJECTIONS; MACULAR DEGENERATION; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VITREOUS BODY;

EID: 75149185468     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181cde727     Document Type: Editorial

References (38)

1. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-870.
2. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
3. Bakri SJ, Risco M, Edwards AO, Pulido JS. Bilateral simultaneous intravitreal injections in the office setting. Am J Ophthalmol 2009;148:66-69.
4. Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than agerelated macular degeneration. Curr Opin Ophthalmol 2009;20: 166-174.
5. Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Opthalmologica 2009;223:370-375.
6. Pulido JS, Bakri SJ, Valyi-Nagy T, Shukla D. Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina 2007;27:1071-1073.
7. Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina 2009;29:129-132.
8. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007;27:399-413.
9. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol 2009;147:761-763.
10. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9:271-285.
11. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1-229.
12. Zhang DW, Shao J, Lin J, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009;325:332-336.
13. Wong M, Ziring D, Korin Y, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008;126:121-136.
14. Lin J, Ziring D, Desai S, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30.
15. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol 2008;146:845-850.
16. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127:819-822.
17. Navarro-Gonzalez JF, Jarque A, Muros M, Mora C, García J. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev 2009;20:165-173.
18. Wong CK, Ho AW, Tong PC, et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol 2007; 149:123-131.
19. Moriwaki Y, Inokuchi T, Yamamoto A, et al. Effect of TNFalpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 2007;44:215-218.
20. Gonzaĺez-Clemente JM, Mauricio D, Richart C, et al. Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. Clin Endocrinol (Oxf) 2005;63:525-529.
21. Nair B, Raval G, Mehta P. TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2008;83:345.
22. Ramos-Casals M, Brito-Zeroń P, Munõz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-251.
23. Fulchiero GJ Jr, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007;56:S65-S67.
24. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008;9:1-14.
25. Information for healthcare professionals: tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). Food and Drug Administration; 2009. Available at: www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/DrugSafety InformationforHeathcareProfessionals/ucm174474.htm. Accessed November 30, 2009.
26. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285.
27. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006;33:31-36.
28. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003;21:241-248.
29. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-1368.
30. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001;358:295-296.
31. Sfikakis PP, Kaklamanis P, Elezoglou A, et al. Infliximab for recurrent sight-threatening ocular inflammation in Adamantiades- Bechet's disease. Ann Intern Med 2004;140:404-406.
32. Markomichelakis N, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004;138:648-650.
33. Sfikakis PP, Markomichelakis N, Theodossiadis GP, Grigoropoulos V, Katsilambros N, Theodossiadis PG. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005;28:445-447.
34. Rosenfeld PJ, Goodman KW. When is off-label drug use in the patient's best interest? Am J Ophthalmol 2009;147:761-763.
35. Beer PM, Wong SJ, Schartman JP, Kulas KE, Hartman CL, Giganti M, et al. Infliximab stability after reconstitution, dilution, and storage under refrigeration. Retina 2010;30:81-84.
36. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events following intravitreal infliximab (Remicade). Retina 2010;30:71-80.
37. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of antitumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008;20:431-435.
38. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005;36:3-10.